Page 796 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 56 Inflammatory Muscle Diseases 767

19. Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in 28. Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of
inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis refractory adult and juvenile dermatomyositis and adult polymyositis: a
1990;68:141–57. randomized, placebo-phase trial. Arthritis Rheum 2013;65:314–24.
20. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the 29. Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement
endoplasmic reticulum stress response in autoimmune myositis: potential in rituximab-treated refractory adult and juvenile dermatomyositis and
role in muscle fiber damage and dysfunction. Arthritis Rheum adult polymyositis. Arthritis Rheumatol 2014;66:740–9.
2005;52:1824–35. 30. The Muscle Study Group. A randomized, pilot trial of etanercept in
21. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen dermatomyositis. Ann Neurol 2011;70:427–36.
expression in regenerating muscle cells in idiopathic inflammatory 31. Park J-K, Yoo H-G, Ahn D-S, et al. Successful treatment for conventional
myopathy. J Exp Med 2005;201:591–601. treatment-resistant dermatomyositis-associated interstitial lung disease
22. Goldstein R, Duvic M, Targoff IN, et al. HLA-D region genes associated with adalimumab. Rheumatol Int 2012;32:3587–90.
with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) 32. Lahouti AH, Brodsky RA, Christopher-Stine L. Idiopathic inflammatory
and other translation-related factors in myositis. Arthritis Rheum myopathy treated with high-dose immunoablative cyclophosphamide—A
1990;33:1240–8. long-term follow-up study. JAMA Neurol 2015;72:1205–6.
23. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of 33. Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis—a
DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A case-based review. Clin Rheumatol 2015;34:609–12.
reductase-associated autoimmune myopathy. Arthritis Care Res 34. Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body
(Hoboken) 2012;64:1233–7. myositis: a retrospective review and a randomized, prospective trial of
24. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with immunosuppressive therapy. Medicine (Baltimore) 1993;72:225–35.
cancer-associated dermatomyositis have antibodies to nuclear matrix 35. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of
protein NXP-2 or transcription intermediary factor 1gamma. Arthritis 32 cases. J Rheumatol 1992;19:1385–9.
Rheum 2013;65:2954–62. 36. Rider LG, Miller FW. Laboratory evaluation of the inflammatory
25. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose myopathies. Clin Diagn Lab Immunol 1995;2:1–9.
intravenous immune globulin infusions as treatment for dermatomyositis. 37. Malattia C, Damasio MB, Madeo A, et al. Whole-body MRI in the
N Engl J Med 1993;329:1993–2000. assessment of disease activity in juvenile dermatomyositis. Ann Rheum
26. Mammen AL, Tiniakou E. Intravenous immune globulin for Dis 2014;73:1083–90.
statin-triggered autoimmune myopathy. N Engl J Med 2015;373:1680–2. 38. Cantwell C, Ryan M, O’Connell M, et al. A comparison of inflammatory
27. Miller FW, Leitman SF, Cronin ME, et al. Controlled trial of plasma myopathies at whole-body turbo STIR MRI. Clin Radiol 2005;
exchange and leukapheresis in polymyositis and dermatomyositis. N Engl 60:261–7.
J Med 1992;326:1380–4. 39. Emery AE. The muscular dystrophies. BMJ 1998;317:991–5.